Structure Therapeutics to Present Aleniglipron Findings at ObesityWeek 2026

SAN FRANCISCO, Oct. 19, 2026 /CourierPR/ -- Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company, will present multiple studies at The Obesity Society's Annual Meeting, ObesityWeek® 2026, taking place from November 14-17, 2026, in National Harbor, MD. The company will showcase findings related to its investigational drug, aleniglipron (GSBR-1290), which is an oral small molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor.

Eastern Time in Exhibit Hall BCD. This presentation will provide insights into the ongoing open-label extension of the ACCESS trial, which is evaluating the long-term safety and efficacy of aleniglipron in participants with overweight or obesity.

This session will delve into the dose-ranging effects of aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist, in the context of the ACCESS trials.

Aleniglipron was designed through Structure Therapeutics' structure-based drug discovery platform and is intended to selectively activate the G-protein signaling pathway. The company's focus is on developing innovative oral small molecule treatments for chronic metabolic conditions, with a particular emphasis on chronic weight management.

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company dedicated to discovering and developing novel treatments for obesity and type 2 diabetes. The company's pipeline includes multiple wholly-owned proprietary clinical-stage oral small molecule compounds, designed to address the scalability limitations of traditional biologic and peptide therapies.

The presentations at ObesityWeek® 2026 will provide valuable updates on the progress of aleniglipron and its potential as a treatment for obesity. These studies are part of the company's ongoing efforts to advance its pipeline and bring new therapies to patients living with chronic metabolic conditions.